The Definitive Guide to Ketamine Therapy Billing & Insurance Reimbursement (2026)

Ketamine therapy is no longer a fringe treatment. With FDA-approved esketamine (Spravato) on the market and off-label IV ketamine infusions being administered at thousands of clinics across the country, billing and reimbursement for ketamine services has become one of the most asked-about — and most misunderstood — topics in behavioral health practice management.

If you're a psychiatrist, PMHNP, or group practice administrator trying to figure out how to actually get paid for ketamine services, you're in the right place. This guide breaks down CPT codes, payer-by-payer coverage realities, documentation requirements, and the most common billing mistakes that trigger denials or audits.

Let's get into it.

Why Ketamine Billing Is So Complicated

Before we get to the codes, it helps to understand why ketamine billing is uniquely messy.

There are actually two distinct clinical tracks here, and they are billed and reimbursed very differently:

Esketamine (Spravato) — The FDA-approved intranasal formulation for treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDD-SI). This is a branded medication with a defined REMS program, J-code billing, and actual (albeit limited) insurance coverage.
IV Ketamine Infusions — Off-label use of racemic ketamine administered intravenously, typically for TRD, PTSD, OCD, chronic pain, and other conditions. This is almost universally paid out-of-pocket by patients, with rare exceptions.

Understanding this distinction isn't just academic — it determines everything about how you code, document, and submit claims.

Spravato (Esketamine) Billing: The Codes You Need

Spravato is the only FDA-approved ketamine-derived treatment with a clear insurance billing pathway. Here's the complete picture.

The J-Code: J0222

J0222 is the HCPCS Level II code for esketamine hydrochloride (Spravato), covering 1 mg of the drug. Since Spravato comes in 28 mg and 56 mg doses, you'll typically bill:

J0222 x 28 units for a 28 mg session
J0222 x 56 units for a 56 mg session

The average reimbursement rate for J0222 varies significantly by payer, but Medicare Part B reimburses approximately $800–$850 per 56 mg session under the 2026 Physician Fee Schedule, factoring in the drug itself plus the required 2-hour in-office observation period.

Commercial payers that cover Spravato (including some plans from Aetna, Cigna, and Blue Cross Blue Shield) tend to reimburse in the range of $700–$1,100 per session, though this varies wildly by contract and region.

Administration and Monitoring Codes

Because Spravato requires a mandatory 2-hour post-administration monitoring period under a REMS-certified provider, you can also bill for:

| CPT/HCPCS Code | Description | Typical Medicare Rate | |---|---|---| | 99213 or 99214 | E/M visit on the day of administration (if medically appropriate) | $92–$167 | | 96372 | Therapeutic injection (if applicable) | ~$25 | | S0013 | Some commercial payers use this for ketamine infusion monitoring | Varies | | 99354 / 99355 | Prolonged services (rarely applicable, use cautiously) | $126 / $67 |

Pro tip: Don't reflexively add an E/M code to every Spravato session. It needs to be a separately identifiable, medically necessary service documented independently from the monitoring. If the visit note is just "patient tolerated infusion well," you're going to lose that charge on audit.

Prior Authorization for Spravato

This is where most practices get tripped up. Almost every commercial payer that covers Spravato requires prior authorization, and the criteria are strict. Common requirements include:

Confirmed diagnosis of TRD (typically defined as failure of 2 or more adequate antidepressant trials)
Adequate trial documentation (dose, duration, prescriber notes)
Concurrent outpatient therapy or medication management
REMS certification of the prescribing clinician AND the healthcare setting

Aetna, UnitedHealthcare, and Cigna all have specific clinical policy bulletins for esketamine. These get updated annually, so check the current version before submitting a PA request.

IV Ketamine Infusion Billing: The Honest Truth

Here's the part most blog posts gloss over: IV ketamine infusions are almost never covered by commercial insurance as a standalone psychiatric treatment. You can bill for them, but expect denials.

That said, there are legitimate CPT codes used in IV ketamine billing, and understanding them matters for practices that offer both infusions and reimbursable services in the same encounter.

CPT Codes for IV Ketamine Infusions

| CPT Code | Description | Notes | |---|---|---| | 96365 | IV infusion, initial, up to 1 hour | Most commonly used for ketamine infusions | | 96366 | IV infusion, each additional hour | Bill for each additional hour beyond the first | | 96367 | Additional sequential infusion, new drug, up to 1 hour | Used when a second agent is added | | 01996 | Daily hospital management of epidural/subarachnoid drug administration | Rarely applicable in outpatient psych settings | | 99213–99215 | E/M services same day | Separately billable if distinct and documented |

Most IV ketamine infusion clinics operate on a cash-pay model, with single infusions priced between $400–$800 and induction series (typically 6 infusions) ranging from $2,400–$4,800. Some practices offer subscription or maintenance packages.

When Does Insurance Cover IV Ketamine?

There are narrow exceptions:

Anesthesia-managed ketamine for procedural sedation (billed under anesthesia codes) is routinely covered
Ketamine for chronic pain management has slightly better (though still inconsistent) coverage under some plans
Hospital-based ketamine for acute suicidality may be covered under inpatient or observation level of care

If you're attempting to bill insurance for outpatient psychiatric IV ketamine, document every clinical decision point and be prepared for medical necessity appeals. Your letter of medical necessity should cite peer-reviewed literature (the American Journal of Psychiatry and Biological Psychiatry have published extensively on ketamine for TRD) and document all prior treatment failures in detail.

Documentation Requirements: This Is Where Claims Live or Die

Whether you're billing Spravato or trying to defend IV ketamine medical necessity, your documentation is everything. Here's what auditors and payer reviewers look for:

For Spravato Claims

Diagnosis specificity — Use the most precise ICD-10 code. For treatment-resistant depression, that's typically:
- F32.89 (Other specified depressive episodes) combined with clinical documentation of treatment resistance
- F33.2 (Major depressive disorder, recurrent, severe without psychotic features)
- F32.3 / F33.3 for MDD with suicidal ideation — required for the MDD-SI indication
Treatment failure documentation — List every prior antidepressant with dosage, duration, and reason for discontinuation. Vague phrases like "patient tried multiple medications" will not hold up.
Monitoring logs — The 2-hour post-dose observation period must be documented. Blood pressure readings at defined intervals, symptom checks, and discharge criteria should all be in the note.
REMS compliance documentation — The REMS program requires specific patient enrollment and monitoring forms. These aren't optional — missing REMS documentation can void reimbursement and expose you to regulatory risk.

For IV Ketamine Claims (Even Cash-Pay)

You still need solid documentation even if you're not billing insurance. Why? Because:

Patients may submit claims to insurance on their own (out-of-network)
You may face audits for any co-billed services (E/M, monitoring)
Good records protect you in the event of adverse outcomes

Every ketamine infusion note should include: indication, prior treatment history, pre-infusion vital signs, infusion protocol (dose mg/kg, rate, duration), dissociative symptoms observed, post-infusion status, and the plan for follow-up.

Common Billing Mistakes That Trigger Denials and Audits

After reviewing hundreds of ketamine-related claim denials, these are the patterns that come up again and again:

Billing J0222 without REMS enrollment — Payers verify this. If your site isn't enrolled, claims will be denied and may be flagged for overpayment recovery.
Unbundling E/M from monitoring — If your E/M note and your monitoring note are essentially the same document, it's going to look like unbundling. They must reflect separate, distinct clinical activities.
Using non-specific ICD-10 codes — F32.9 ("Major depressive disorder, single episode, unspecified") is technically valid but weak for medical necessity arguments. Use the most specific code available.
Missing prior authorization — Seems obvious, but PA requirements for Spravato change frequently. Always verify before the session, not after.
Incorrect units on J0222 — This is a surprisingly common error. Billing 1 unit of J0222 when you administered 56 mg means you're billing for 1 mg. Always calculate units based on the dose administered.
Not documenting medical necessity for add-on E/M codes — If you're billing 99214 alongside J0222, the note must show a separately identifiable evaluation with history, assessment, and clinical decision-making — not just infusion monitoring.

Payer-by-Payer Spravato Coverage Snapshot (2026)

| Payer | Covers Spravato? | PA Required? | Key Requirements | |---|---|---|---| | Medicare Part B | ✅ Yes | Yes (LCD) | TRD diagnosis, 2+ failed antidepressants, REMS | | Medicaid | Varies by state | Yes (most states) | Check state-specific PDL and PA criteria | | Aetna | ✅ Yes (with criteria) | Yes | CPB 0812; TRD or MDD-SI; concurrent treatment | | UnitedHealthcare | ✅ Yes (with criteria) | Yes | Medical policy guideline; step therapy required | | Cigna | ✅ Yes (with criteria) | Yes | Coverage Policy; 2+ failed trials required | | BCBS (varies by plan) | Partial | Yes | Varies significantly by state and plan type | | Humana | ✅ Limited | Yes | Typically requires TRD criteria and REMS | | Tricare | ✅ Yes | Yes | Military treatment facility or authorized provider |

Always verify current coverage policies directly with the payer. These policies update frequently, and a "covered" status from 2024 may have different criteria in 2026.

Coding for Ketamine Alongside Other Behavioral Health Services

Many psychiatry practices and behavioral health group practices administer Spravato as part of a broader treatment program that includes psychotherapy, medication management, and case coordination. Here's how to handle the coding:

Ketamine + Psychotherapy same day: You can bill psychotherapy (90832–90837) and J0222 on the same day if the therapy session is a distinct, separately documented encounter — not the monitoring period repackaged as therapy.
Medication management + Ketamine: An E/M code (99213–99215) can be billed with J0222 using modifier 25 to indicate a significant, separately identifiable service. The documentation must be robust.
Collaborative care and care coordination: If your practice uses the Collaborative Care Model (CoCM), ketamine services can be layered into the care team workflow — but billing codes (99492–99494) must reflect the care manager's time, not the infusion.

FAQ: Ketamine Therapy Billing & Reimbursement

1. Can a therapist (LPC, LCSW, LMFT) bill for ketamine services?

Not directly. Ketamine administration requires a licensed prescriber (MD, DO, APRN/NP, or PA with prescriptive authority). However, therapists practicing in a group setting can bill for psychotherapy services delivered on the same day as ketamine treatment — as long as those services are separate, documented, and not part of the monitoring period.

2. What ICD-10 code do I use for treatment-resistant depression?

There is no single ICD-10 code that explicitly says "treatment-resistant depression." The most commonly accepted approach is to use F32.89 (Other specified depressive episodes) or F33.89 (Other specified depressive disorder, recurrent) and support the treatment-resistance designation through clinical documentation of prior failed trials.

3. How long does Spravato prior authorization take?

Most payers process standard PA requests within 3–5 business days. Urgent or expedited requests may be processed within 24–72 hours. Given the complexity of TRD cases and the documentation required, build in at least 1–2 weeks for the initial PA process when starting a new patient on Spravato.

4. Can patients use their HSA or FSA for IV ketamine infusions?

Yes — because IV ketamine infusions are a legitimate medical treatment (even if not FDA-approved for psychiatric indications), they generally qualify as an eligible HSA/FSA expense. This is worth communicating to patients as a way to reduce out-of-pocket burden for cash-pay services.

5. What modifier should I use when billing E/M with Spravato on the same day?

Use modifier 25 on the E/M code to indicate that the evaluation and management service is a significant, separately identifiable service performed on the same day as the procedure or service. Without modifier 25, the E/M will almost certainly be bundled and denied.

6. Is teleprescribing of ketamine (at-home ketamine) billable differently?

Yes — and it's an evolving area. Oral/sublingual ketamine prescribed via telehealth (e.g., through platforms like Mindbloom or Ketamine Clinics Los Angeles) is handled differently. The prescribing visit is billed as a standard telehealth E/M (with appropriate place of service code 02 or 10), and there is no J-code involved since the medication is dispensed through pharmacy channels. This is entirely cash-pay in most cases.

How Mozu Health Helps Ketamine Providers Get Documentation Right

Ketamine therapy sits at the intersection of clinical complexity, regulatory scrutiny, and billing precision — and that's exactly where documentation errors are most costly.

Mozu Health is an AI-powered clinical documentation platform built specifically for behavioral health providers. For psychiatrists, PMHNPs, and group practices offering Spravato or IV ketamine services, Mozu Health helps you:

Generate audit-ready notes that meet payer-specific medical necessity standards for ketamine and TRD documentation
Track prior treatment failures with structured, searchable documentation — the kind of detail that wins PA approvals and survives insurance audits
Stay HIPAA-compliant with every note, monitoring log, and patient communication stored securely
Reduce documentation time so your clinical team spends less time charting and more time with patients
Prepare for audits before they happen with built-in compliance checks and documentation scoring

Whether you're billing J0222 for Spravato or defending the medical necessity of an IV infusion series, the strength of your documentation is what determines your outcome.

Ready to Protect Your Ketamine Practice with Better Documentation?

Billing for ketamine services is hard enough without worrying about whether your notes will hold up. Mozu Health takes the documentation burden off your plate so you can focus on delivering care — and get paid for it.

Try Mozu Health free at mozuhealth.com →

See how AI-powered clinical documentation can reduce your audit risk, accelerate reimbursement, and keep your behavioral health practice running at its best.

This article is intended for educational purposes and does not constitute legal, billing, or clinical advice. CPT codes, reimbursement rates, and payer policies are subject to change. Always verify current coding guidelines with CMS, AMA, and individual payers before submitting claims.

Ketamine Therapy Billing & Insurance Reimbursement Guide 2026